Ignite Creation Date:
2025-12-24 @ 2:53 PM
Ignite Modification Date:
2025-12-26 @ 1:22 PM
Study NCT ID:
NCT03402659
Status:
COMPLETED
Last Update Posted:
2021-10-27
First Post:
2018-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2020-09-17', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D000544', 'term': 'Alzheimer Disease'}], 'ancestors': [{'id': 'D003704', 'term': 'Dementia'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D024801', 'term': 'Tauopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C464966', 'term': 'VX-745'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'jconway@eippharma.com', 'phone': '(617) 744-4400', 'title': 'Jennifer Conway, Associate Director of Clinical Development', 'organization': 'EIP Pharma'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Up to 29 weeks. AEs occurring from when the subject signed the ICF until up to 30 days after the last dose were collected. Any AEs occurring before the start of treatment (i.e., before the first dose of the investigational product) were recorded in the medical history.', 'description': 'Any sign, symptom, or disease present before starting the treatment period were only considered AEs if they worsen after starting the treatment period.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo', 'otherNumAtRisk': 83, 'deathsNumAtRisk': 83, 'otherNumAffected': 16, 'seriousNumAtRisk': 83, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).', 'otherNumAtRisk': 78, 'deathsNumAtRisk': 78, 'otherNumAffected': 18, 'seriousNumAtRisk': 78, 'deathsNumAffected': 0, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Upper Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 6, 'numAffected': 5}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}, {'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}], 'seriousEvents': [{'term': 'Multiple Myeloma', 'notes': 'Multiple Myeloma occurred in one subject. It was not considered related to neflamapimod.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}, {'term': 'Hypokalemia', 'notes': 'One SAE of Hypokalemia was reported. It was considered not related to neflamapimod.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}, {'term': 'Non-Cardiac Chest Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 83, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 78, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (20.1)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '71', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.09679', 'spread': '0.074840', 'groupId': 'OG000'}, {'value': '-0.15776', 'spread': '0.085805', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.564', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.06098', 'ciLowerLimit': '-0.26973', 'ciUpperLimit': '0.14777', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.105548', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': "Combined change from baseline in z-scores of total and delayed recall on the Hopkins Verbal Learning Test - Revised (HVLT-R) in neflamapimod-treated subjects compared to placebo. The primary endpoint was analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate.\n\nFor baseline total and delayed recall, a z-score for each subject is defined by z=(x-m)/s where x is the subject's recall at baseline, and m and s are the overall mean and overall standard deviation of recall at baseline across all subjects. A composite baseline z-score for each subject is calculated using equal weighting in the following way: Z=0.5\\*z-score for total recall at baseline + 0.5\\*z-score for delayed recall at baseline. For HVLT-R, higher score indicates improvement.", 'unitOfMeasure': 'Z-score', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who had analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Wechsler Memory Scale (WMS) Immediate and Delayed Recall', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '71', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '16.6', 'spread': '2.09', 'groupId': 'OG000'}, {'value': '16.0', 'spread': '2.07', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.823', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.6', 'ciLowerLimit': '-6.0', 'ciUpperLimit': '4.8', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.72', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': 'Change from baseline in Wechsler Memory Scale(WMS) immediate and delayed recall composites in neflamapimod-treated subjects compared to placebo. WMS scores were analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate. Composite scores for immediate and delayed recall are the combination of all immediate and delayed recall task raw scores and ranges from 0-228. A higher score indicates improvement.\n\nThe following tests in WMS are done both for immediate and delayed recall: Logical Memory test, in which subject is read a story; Verbal-Paired Associates, in which subject is given pairs of words and asked remember which words go together; and Visual Reproduction, in which subject is given drawings of specific shapes', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who had analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '78', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '1.0', 'spread': '0.20', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '0.21', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.806', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.1', 'ciLowerLimit': '-0.4', 'ciUpperLimit': '0.6', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.25', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': 'Change from baseline in total score of Clinical Dementia Rating Scale - Sum of Boxes (range 0-18) in neflamapimod-treated subjects compared to placebo. CDR-SB scores were analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate. CDR-SB score is calculated by adding the individual scores from 6 domains, Memory, Orientation, Judgement and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. CDR-SB scores range from 0-18, where a lower score indicates improvement. The scale is administered in a semi-structured interview format with both the patient and the caregiver/informant.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who had analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Mini-Mental State Examination (MMSE)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '79', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.31', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '0.33', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.489', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.3', 'ciLowerLimit': '-1.0', 'ciUpperLimit': '0.5', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.39', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 26 Weeks (Follow-up visit, 2 weeks from end of dosing)', 'description': "Changes from baseline in Mini-Mental State Examination (MMSE) scores were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value. The MMSE is scored from 0-30 with a higher score indicating improvement. The MMSE includes questions that test orientation, attention, memory, language and visual-spatial skills.", 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who had analyzable results at Baseline and Follow-up Visit (2 weeks post-treatment)'}, {'type': 'SECONDARY', 'title': 'Cerebrospinal Fluid Total Tau', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '10.0', 'spread': '6.83', 'groupId': 'OG000'}, {'value': '-8.6', 'spread': '7.36', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.031', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-18.8', 'ciLowerLimit': '-35.8', 'ciUpperLimit': '-1.8', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.60', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from, baseline in Total Tau (t-tau) were compared using an ANCOVA with treatment group, background ADspecific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.", 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants with analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Cerebrospinal Fluid Phospho-tau', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.9', 'spread': '0.63', 'groupId': 'OG000'}, {'value': '-1.1', 'spread': '0.68', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.012', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.0', 'ciLowerLimit': '-3.6', 'ciUpperLimit': '-0.5', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.79', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Phospho-Tau (p-tau181) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.", 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who had analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Cerebrospinal Fluid Amyloid Beta 1-40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '399.7', 'spread': '249.18', 'groupId': 'OG000'}, {'value': '282.3', 'spread': '268.58', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.709', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-117.4', 'ciLowerLimit': '-738.9', 'ciUpperLimit': '504.2', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '314', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Amyloid beta (AB1-40) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.", 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who had analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Cerebrospinal Fluid Amyloid Beta 1-42', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '31.1', 'spread': '12.70', 'groupId': 'OG000'}, {'value': '10.0', 'spread': '13.75', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.192', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.0', 'ciLowerLimit': '-52.7', 'ciUpperLimit': '10.7', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '16.03', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Amyloid beta (AB1-42) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.", 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who had analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Cerebrospinal Fluid Neurogranin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '11.1', 'spread': '9.16', 'groupId': 'OG000'}, {'value': '-9.9', 'spread': '9.82', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.068', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.0', 'ciLowerLimit': '-43.6', 'ciUpperLimit': '1.6', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '11.43', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Neurogranin were compared using an ANCOVA with treatment group, background ADspecific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.", 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants with analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Cerebrospinal Fluid Neurofilament Light Chain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '231.9', 'spread': '61.31', 'groupId': 'OG000'}, {'value': '121.7', 'spread': '66.92', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.156', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-110.1', 'ciLowerLimit': '-262.7', 'ciUpperLimit': '42.4', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '77.11', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Neurofilament Light Chain (NFL) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.", 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants with analyzable results at Baseline and Week 24'}, {'type': 'SECONDARY', 'title': 'Cerebrospinal Fluid P-tau/AB1-42 Ratio', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'OG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.0', 'spread': '0', 'groupId': 'OG000'}, {'value': '-0.0', 'spread': '0', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.590', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.0', 'ciLowerLimit': '-0.0', 'ciUpperLimit': '0.0', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0', 'groupDescription': 'Mean change from baseline neflamapimod vs placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': "Changes in the ratio of Phospho-Tau/Amyloid Beta (p-tau181/AB1-42) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.", 'unitOfMeasure': 'ratio', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants with analyzable results at Baseline and Week 24'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'FG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '83'}, {'groupId': 'FG001', 'numSubjects': '78'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '78'}, {'groupId': 'FG001', 'numSubjects': '73'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '5'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '83', 'groupId': 'BG000'}, {'value': '78', 'groupId': 'BG001'}, {'value': '161', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo Arm', 'description': 'Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo'}, {'id': 'BG001', 'title': 'Neflamapimod Arm', 'description': 'Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '16', 'groupId': 'BG001'}, {'value': '30', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '69', 'groupId': 'BG000'}, {'value': '62', 'groupId': 'BG001'}, {'value': '131', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '72.6', 'groupId': 'BG000', 'lowerLimit': '56', 'upperLimit': '85'}, {'value': '70.8', 'groupId': 'BG001', 'lowerLimit': '56', 'upperLimit': '84'}, {'value': '71.8', 'groupId': 'BG002', 'lowerLimit': '56', 'upperLimit': '85'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '43', 'groupId': 'BG000'}, {'value': '37', 'groupId': 'BG001'}, {'value': '80', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '40', 'groupId': 'BG000'}, {'value': '41', 'groupId': 'BG001'}, {'value': '81', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '79', 'groupId': 'BG000'}, {'value': '77', 'groupId': 'BG001'}, {'value': '156', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Netherlands', 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}]}, {'title': 'United States', 'categories': [{'measurements': [{'value': '38', 'groupId': 'BG000'}, {'value': '35', 'groupId': 'BG001'}, {'value': '73', 'groupId': 'BG002'}]}]}, {'title': 'Czechia', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}]}, {'title': 'Denmark', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}, {'title': 'United Kingdom', 'categories': [{'measurements': [{'value': '29', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '52', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Weight', 'classes': [{'categories': [{'measurements': [{'value': '74.4', 'groupId': 'BG000', 'lowerLimit': '45', 'upperLimit': '111'}, {'value': '75.6', 'groupId': 'BG001', 'lowerLimit': '48.9', 'upperLimit': '161'}, {'value': '75', 'groupId': 'BG002', 'lowerLimit': '45', 'upperLimit': '161'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Kg', 'dispersionType': 'FULL_RANGE'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-08-27', 'size': 680268, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2020-07-23T15:52', 'hasProtocol': True}, {'date': '2019-07-30', 'size': 706420, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-07-23T15:53', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Double-blind, placebo-controlled'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 161}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-12-29', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-09', 'completionDateStruct': {'date': '2019-07-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-09-28', 'studyFirstSubmitDate': '2018-01-11', 'resultsFirstSubmitDate': '2020-08-26', 'studyFirstSubmitQcDate': '2018-01-11', 'lastUpdatePostDateStruct': {'date': '2021-10-27', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-09-28', 'studyFirstPostDateStruct': {'date': '2018-01-18', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2021-10-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-06-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R)', 'timeFrame': 'Baseline and 24 weeks', 'description': "Combined change from baseline in z-scores of total and delayed recall on the Hopkins Verbal Learning Test - Revised (HVLT-R) in neflamapimod-treated subjects compared to placebo. The primary endpoint was analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate.\n\nFor baseline total and delayed recall, a z-score for each subject is defined by z=(x-m)/s where x is the subject's recall at baseline, and m and s are the overall mean and overall standard deviation of recall at baseline across all subjects. A composite baseline z-score for each subject is calculated using equal weighting in the following way: Z=0.5\\*z-score for total recall at baseline + 0.5\\*z-score for delayed recall at baseline. For HVLT-R, higher score indicates improvement."}], 'secondaryOutcomes': [{'measure': 'Wechsler Memory Scale (WMS) Immediate and Delayed Recall', 'timeFrame': 'Baseline and 24 weeks', 'description': 'Change from baseline in Wechsler Memory Scale(WMS) immediate and delayed recall composites in neflamapimod-treated subjects compared to placebo. WMS scores were analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate. Composite scores for immediate and delayed recall are the combination of all immediate and delayed recall task raw scores and ranges from 0-228. A higher score indicates improvement.\n\nThe following tests in WMS are done both for immediate and delayed recall: Logical Memory test, in which subject is read a story; Verbal-Paired Associates, in which subject is given pairs of words and asked remember which words go together; and Visual Reproduction, in which subject is given drawings of specific shapes'}, {'measure': 'Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)', 'timeFrame': 'Baseline and 24 weeks', 'description': 'Change from baseline in total score of Clinical Dementia Rating Scale - Sum of Boxes (range 0-18) in neflamapimod-treated subjects compared to placebo. CDR-SB scores were analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate. CDR-SB score is calculated by adding the individual scores from 6 domains, Memory, Orientation, Judgement and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. CDR-SB scores range from 0-18, where a lower score indicates improvement. The scale is administered in a semi-structured interview format with both the patient and the caregiver/informant.'}, {'measure': 'Mini-Mental State Examination (MMSE)', 'timeFrame': 'Baseline and 26 Weeks (Follow-up visit, 2 weeks from end of dosing)', 'description': "Changes from baseline in Mini-Mental State Examination (MMSE) scores were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value. The MMSE is scored from 0-30 with a higher score indicating improvement. The MMSE includes questions that test orientation, attention, memory, language and visual-spatial skills."}, {'measure': 'Cerebrospinal Fluid Total Tau', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from, baseline in Total Tau (t-tau) were compared using an ANCOVA with treatment group, background ADspecific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value."}, {'measure': 'Cerebrospinal Fluid Phospho-tau', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Phospho-Tau (p-tau181) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value."}, {'measure': 'Cerebrospinal Fluid Amyloid Beta 1-40', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Amyloid beta (AB1-40) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value."}, {'measure': 'Cerebrospinal Fluid Amyloid Beta 1-42', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Amyloid beta (AB1-42) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value."}, {'measure': 'Cerebrospinal Fluid Neurogranin', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Neurogranin were compared using an ANCOVA with treatment group, background ADspecific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value."}, {'measure': 'Cerebrospinal Fluid Neurofilament Light Chain', 'timeFrame': 'Baseline and 24 weeks', 'description': "Change from baseline in Neurofilament Light Chain (NFL) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value."}, {'measure': 'Cerebrospinal Fluid P-tau/AB1-42 Ratio', 'timeFrame': 'Baseline and 24 weeks', 'description': "Changes in the ratio of Phospho-Tau/Amyloid Beta (p-tau181/AB1-42) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value."}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Alzheimer Disease']}, 'referencesModule': {'references': [{'pmid': '34044875', 'type': 'DERIVED', 'citation': "Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P; REVERSE-SD Study Investigators. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. Alzheimers Res Ther. 2021 May 27;13(1):106. doi: 10.1186/s13195-021-00843-2."}, {'pmid': '33974419', 'type': 'DERIVED', 'citation': 'Tormahlen NM, Martorelli M, Kuhn A, Maier F, Guezguez J, Burnet M, Albrecht W, Laufer SA, Koch P. Design and Synthesis of Highly Selective Brain Penetrant p38alpha Mitogen-Activated Protein Kinase Inhibitors. J Med Chem. 2022 Jan 27;65(2):1225-1242. doi: 10.1021/acs.jmedchem.0c01773. Epub 2021 May 11.'}]}, 'descriptionModule': {'briefSummary': "This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate significant improvement relative to placebo-treatment in episodic memory function, as assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.", 'detailedDescription': 'Details provided elsewhere.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '85 Years', 'minimumAge': '55 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Men and women age 55 to 85 years, inclusive.\n2. Willing and able to provide informed consent.\n3. Must have mild cognitive impairment (MCI) or mild AD with evidence of progression ("Mild-AD"), as defined by the following:\n\n 1. CDR-Global Score of 0.5 or 1.0, with CDR memory subscore of at least 0.5.\n 2. MMSE score ranging from 20 to 28, inclusive.\n 3. Positive biomarker for AD, as defined by a CSF Aβ1-42R below the threshold and phospho-tau above the threshold for the assay utilized in the study and assessed by the central laboratory.\n4. Computed tomography (CT) or magnetic resonance imaging (MRI) findings within 2 years of Screening that are compatible with AD and no other pathologic processes that might potentially account for the subject\'s cognitive impairment.\n5. If the subject is taking a single drug for AD (e.g., donepezil or other cholinesterase inhibitors or memantine; dual therapy is excluded), he/she has been on a stable dose for at least 2 months prior to baseline, and the dose must remain unchanged during the study unless required for management of adverse events (AEs).\n6. Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.\n7. Must have reliable informant or caregiver.\n\nExclusion Criteria:\n\n1. Evidence that the primary basis for cognitive impairment is neurodegenerative disease other than AD, including, but not limited to, vascular dementia, dementia with Lewy bodies, and Parkinson\'s disease.\n2. Suicidality, defined as active suicidal thoughts within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator\'s opinion, at serious risk of suicide.\n3. History of major and active psychiatric disorder, moderate to severe depressive symptoms, and or other concurrent medical condition that, EIP-VX17-745-304, Version 1.0, 17 November, 2017 Page 7 of 46 EIP Pharma, LLC Confidential in the opinion of the Investigator, might compromise safety and/or compliance with study requirements.\n4. Diagnosis of alcohol or drug abuse within the previous 2 years.\n5. History of cancer within the last 5 years, except basal cell carcinoma, squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.\n6. Poorly controlled clinically significant medical illness.\n7. History of serum B12 abnormality, anemia with hemoglobin ≤10 g/dL, thyroid function abnormality, electrolyte abnormality, or positive syphilis serology that have not been corrected and/or otherwise addressed.\n8. History of epilepsy or unexplained seizure within the past 5 years.\n9. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3 × the upper limit of normal (ULN), total bilirubin \\>2 × ULN, and/or International Normalized Ratio (INR) \\>1.5\n10. Known human immunodeficiency virus, hepatitis B, or active hepatitis C virus infection.\n11. Subject participated in a study of an investigational drug less than 3 months or 5 half-lives of the investigation drug, whichever is longer, before enrollment in this study.'}, 'identificationModule': {'nctId': 'NCT03402659', 'acronym': 'REVERSE-SD', 'briefTitle': "Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease", 'organization': {'class': 'INDUSTRY', 'fullName': 'EIP Pharma Inc'}, 'officialTitle': "A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease", 'orgStudyIdInfo': {'id': 'EIP-VX17-745-304'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'neflamapimod', 'description': '40 mg hard gelatin capsules, taken twice daily with food.', 'interventionNames': ['Drug: neflamapimod']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'placebo', 'description': 'hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.', 'interventionNames': ['Other: placebo']}], 'interventions': [{'name': 'neflamapimod', 'type': 'DRUG', 'otherNames': ['VX-745'], 'description': '40 mg neflamapimod capsule', 'armGroupLabels': ['neflamapimod']}, {'name': 'placebo', 'type': 'OTHER', 'description': 'matching placebo capsule', 'armGroupLabels': ['placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90807', 'city': 'Long Beach', 'state': 'California', 'country': 'United States', 'facility': 'Alliance for Research', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '92103', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Pacific Research Network', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '92705', 'city': 'Santa Ana', 'state': 'California', 'country': 'United States', 'facility': 'CITrials', 'geoPoint': {'lat': 33.74557, 'lon': -117.86783}}, {'zip': '93065', 'city': 'Simi Valley', 'state': 'California', 'country': 'United States', 'facility': 'Southern California Research, LLC', 'geoPoint': {'lat': 34.26945, 'lon': -118.78148}}, {'zip': '92591', 'city': 'Temecula', 'state': 'California', 'country': 'United States', 'facility': 'Viking Clinical Research', 'geoPoint': {'lat': 33.49364, 'lon': -117.14836}}, {'zip': '33176', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Miami Dade Medical Research Institute', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '34761', 'city': 'Ocoee', 'state': 'Florida', 'country': 'United States', 'facility': 'Sensible Healthcare, LLC', 'geoPoint': {'lat': 28.56917, 'lon': -81.54396}}, {'zip': '32502', 'city': 'Pensacola', 'state': 'Florida', 'country': 'United States', 'facility': 'Anchor Neuroscience', 'geoPoint': {'lat': 30.42131, 'lon': -87.21691}}, {'zip': '32127', 'city': 'Port Orange', 'state': 'Florida', 'country': 'United States', 'facility': 'Progressive Medical Research', 'geoPoint': {'lat': 29.13832, 'lon': -80.99561}}, {'zip': '33713', 'city': 'St. Petersburg', 'state': 'Florida', 'country': 'United States', 'facility': 'Suncoast Neuroscience Associates, Inc.', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'zip': '32789', 'city': 'Winter Park', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Premier Research Institute', 'geoPoint': {'lat': 28.6, 'lon': -81.33924}}, {'zip': '83704', 'city': 'Boise', 'state': 'Idaho', 'country': 'United States', 'facility': 'Northwest Clinical Trials', 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '02129', 'city': 'Charlestown', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'MassGeneral Institute for Neurodegenerative Disease', 'geoPoint': {'lat': 42.37787, 'lon': -71.062}}, {'zip': '10036', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Manhattan Behavioral Medicine', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '28270', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': "Alzheimer's Memory Center and Research Institute", 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '98007', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Northwest Clinical Research Center', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '565 01', 'city': 'Choceň', 'country': 'Czechia', 'facility': 'Neuro HK, s.r.o. POLIKLINIKA CHOCEŇ, a.s.', 'geoPoint': {'lat': 50.00161, 'lon': 16.22303}}, {'zip': '702 00', 'city': 'Moravská Ostrava', 'country': 'Czechia', 'facility': 'Cerebrovaskulární poradna s.r.o.', 'geoPoint': {'lat': 49.84249, 'lon': 18.26727}}, {'zip': '100 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Clintrial S.R.O', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '109 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Private Psychiatric Centre', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '516 01', 'city': 'Rychnov nad Kněžnou', 'country': 'Czechia', 'facility': 'Vestra Clinics S.R.O', 'geoPoint': {'lat': 50.16284, 'lon': 16.27488}}, {'zip': 'DK-9000', 'city': 'Aalborg', 'country': 'Denmark', 'facility': 'CCBR Clinical Research, Aalborg', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': 'DK-2750', 'city': 'Ballerup Municipality', 'country': 'Denmark', 'facility': 'CCBR Clinical Research, Ballerup', 'geoPoint': {'lat': 55.73165, 'lon': 12.36328}}, {'zip': 'DK-7100', 'city': 'Vejle', 'country': 'Denmark', 'facility': 'CCBR Clinical Research, Vejle', 'geoPoint': {'lat': 55.70927, 'lon': 9.5357}}, {'zip': '5223 GZ', 'city': "'s-Hertogenbosch", 'country': 'Netherlands', 'facility': 'Jeroen Bosch Ziekenhuis', 'geoPoint': {'lat': 51.69917, 'lon': 5.30417}}, {'zip': '1081 GM', 'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Alzheimer Research Center', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '4817 CK', 'city': 'Breda', 'country': 'Netherlands', 'facility': 'Amphia Ziekhuis', 'geoPoint': {'lat': 51.58656, 'lon': 4.77596}}, {'zip': 'S75 3DL', 'city': 'Barnsley', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research Tankersley', 'geoPoint': {'lat': 53.55, 'lon': -1.48333}}, {'zip': 'B16 8LT', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'Re:Cognition Health Birmingham', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'FY2 0JH', 'city': 'Blackpool', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research Blackpool', 'geoPoint': {'lat': 53.81667, 'lon': -3.05}}, {'zip': 'CB21 5EF', 'city': 'Cambridge', 'country': 'United Kingdom', 'facility': 'Fulbourn Hospital', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'LS10 1DU', 'city': 'Leeds', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research Leeds', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'zip': 'L34 1BH', 'city': 'Liverpool', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research Liverpool', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'W1G 9JF', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Re:Cognition Health London', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'WC1X 8QD', 'city': 'London', 'country': 'United Kingdom', 'facility': 'St. Pancras Clinical Research', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M13 9NQ', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research Manchester', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'PL5 8BT', 'city': 'Plymouth', 'country': 'United Kingdom', 'facility': 'Re:Cognition Health Plymouth', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'zip': 'WA22 8WA', 'city': 'Warrington', 'country': 'United Kingdom', 'facility': '5 Boroughs/North West Boroughs Healthcare NHS Foundation Trust', 'geoPoint': {'lat': 53.39254, 'lon': -2.58024}}], 'overallOfficials': [{'name': 'John Alam, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'EIP Pharma'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'EIP Pharma Inc', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Worldwide Clinical Trials', 'class': 'OTHER'}, {'name': 'Amsterdam UMC, location VUmc', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}